Nov 27 (Reuters) - Canada's public health agency has
approved Novo Nordisk's weight loss drug Wegovy to
reduce the risk of nonfatal myocardial infarction, or heart
attack, in adults with established cardiovascular disease, the
drugmaker said on Wednesday.